OTC: HLYK
HealthLynked CorpCIK 0001680139 · SIC 8011 · Offices of Doctors
Micro
Revenue $2M
Assets $2M
as of Aug 23, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.
10-Q
Filed Aug 14, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
8-K
Filed Jul 16, 2026
· Period ending Jul 13, 2026
Summary not yet generated.
Partner
Trade HLYK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
S-1/A
Filed May 29, 2026
Red flag
HealthLynked Q1 loss widens 54% as revenue falls 44%; cash dwindles to $24K
5 material changes detected. Sign up free to read the summary.
10-Q
Filed May 15, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
S-1/A
Filed Apr 30, 2026
Summary not yet generated.
10-K
Filed Mar 31, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
S-1
Filed Feb 10, 2026
Summary not yet generated.
8-K
Filed Feb 6, 2026
· Period ending Feb 2, 2026
Summary not yet generated.
8-K
Filed Dec 12, 2025
· Period ending Dec 1, 2025
Summary not yet generated.
10-Q
Filed Nov 19, 2025
· Period ending Sep 30, 2025
Summary not yet generated.
10-K
Filed Mar 31, 2025
· Period ending Dec 31, 2024
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Patient service revenue, net | 230,515 | 572,840 | 649,128 | 1,324,855 |
| Subscription revenue | 7,187 | 7,099 | 10,681 | 16,683 |
| Product revenue | 12,128 | 12,421 | 13,486 | 25,030 |
| Total revenue | 249,830 | 592,360 | 673,295 | 1,366,568 |
| Operating Expenses and Costs | ||||
| Practice salaries and benefits | 139,223 | 285,379 | 281,327 | 687,745 |
| Other practice operating expenses | 122,185 | 247,395 | 222,004 | 561,371 |
| Cost of product revenue | (520) | 15,978 | 8,514 | 33,794 |
| Selling, general and administrative expenses | 517,489 | 451,755 | 1,364,770 | 1,081,170 |
| Depreciation and amortization | 10,229 | 27,238 | 36,269 | 55,262 |
| Total Operating Expenses and Costs | 788,606 | 1,027,745 | 1,912,884 | 2,419,342 |
| Loss from operations | (538,776) | (435,385) | (1,239,589) | (1,052,774) |
| Other Income (Expenses) | ||||
| Gain on extinguishment of debt | --- | 132,246 | 1,328,069 | 174,972 |
| Loss on change in fair value of debt | (143,123) | (105,502) | (2,323,649) | (154,688) |
| Gain on change in fair value of derivative financial instruments | 32,599 | 694 | 64,768 | 45,732 |
| Amortization of original issue discounts on notes payable | (150,954) | (214,580) | (238,938) | (619,693) |
| Interest expense and other | (19,451) | (78,511) | (31,670) | (145,526) |
| Total other income (expenses) | (280,929) | (265,653) | (1,201,420) | (699,203) |
| Loss before provision for income taxes | (819,705) | (701,038) | (2,441,009) | (1,751,977) |
| Provision for income taxes | --- | --- | --- | --- |
| Net loss | (819,705) | (701,038) | (2,441,009) | (1,751,977) |
| Deemed dividend | --- | --- | (36,347) | --- |
| Net loss to common shareholders | (819,705) | (701,038) | (2,477,356) | (1,751,977) |
| Net loss per share, basic and diluted: | ||||
| Basic | (0.28) | (0.25) | (0.84) | (0.62) |
| Fully diluted | (0.28) | (0.25) | (0.84) | (0.62) |
| Net loss to common shareholders per share, basic and diluted: | ||||
| Basic | (0.28) | (0.25) | (0.85) | (0.62) |
| Fully diluted | (0.28) | (0.25) | (0.85) | (0.62) |
| Weighted average number of common shares: | ||||
| Basic | 2,942,170 | 2,819,472 | 2,922,186 | 2,819,472 |
| Fully diluted | 2,942,170 | 2,819,472 | 2,922,186 | 2,819,472 |
Condensed Consolidated Balance Sheets
| Description | June 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash | 12,844 | 37,136 |
| Inventory, net | 18,300 | 17,962 |
| Prepaid expenses and other current assets | 50,176 | 32,935 |
| Contingent sale consideration receivable | 1,463,518 | 1,463,518 |
| Total Current Assets | 1,544,838 | 1,551,551 |
| Property and equipment, net of accumulated depreciation of $764,979 and $728,710 as of June 30, 2026 and December 31, 2025, respectively | 38,437 | 74,705 |
| Right of use lease assets | 9,715 | 76,090 |
| Total Assets | 1,592,990 | 1,702,346 |
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||
| Current Liabilities | ||
| Accounts payable, accrued expenses and other current liabilities | 1,071,233 | 821,480 |
| Contract liabilities | 28,366 | 25,924 |
| Lease liability, current portion | 9,715 | 75,168 |
| Derivative financial instruments | 23,663 | 23,846 |
| Notes payable and other amounts due to related party, net of unamortized discounts of $5,261 and $-0- as of June 30, 2026 and December 31, 2025, respectively | 7,041,218 | 5,533,231 |
| Notes payable, current portion, net of unamortized discounts of $134,091 and $109,027 as of June 30, 2026 and December 31, 2025, respectively | 578,088 | 389,652 |
| Indemnification liability | 143,974 | 143,974 |
| Total Current Liabilities | 8,896,257 | 7,013,275 |
| Long-Term Liabilities | ||
| Lease liability, long term portion | --- | 922 |
| Government and other notes payable, long term portion | 450,000 | 450,000 |
| Total Liabilities | 9,346,257 | 7,464,197 |
| Commitments and contingencies (Note 14) | ||
| Shareholders’ Deficit | ||
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 2,953,225 and 2,881,104 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 295 | 288 |
| Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 2,750 | 2,750 |
| Common stock issuable, $0.0001 par value; 132,597 and 22,052 as of June 30, 2026 and December 31, 2025, respectively | 49,510 | 61,349 |
| Additional paid-in capital | 45,210,752 | 44,712,980 |
| Accumulated deficit | (53,016,574) | (50,539,218) |
| Total Shareholders’ Deficit | (7,753,267) | (5,761,851) |
| Total Liabilities and Shareholders’ Deficit | 1,592,990 | 1,702,346 |
Condensed Consolidated Statement of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash Flows from Operating Activities | ||
| Net loss | (2,441,009) | (1,751,977) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 36,269 | 55,262 |
| Stock based compensation, including amortization of deferred equity compensation | 385,759 | 12,392 |
| Gain on change in fair value of derivative financial instruments | (64,768) | (45,732) |
| Amortization of debt discount | 238,938 | 619,693 |
| Gain on extinguishment of debt | (1,328,069) | (174,972) |
| Loss on change in fair value of debt | 2,323,649 | 154,688 |
| Changes in operating assets and liabilities: | ||
| Inventory | (339) | 17,098 |
| Contract assets | --- | 9,381 |
| Prepaid expenses and other current assets | (17,241) | 29,461 |
| Right of use lease assets | 55,497 | 122,121 |
| Accounts payable and accrued expenses | 292,260 | 302,982 |
| Lease liability | (55,497) | (123,153) |
| Contract liabilities | 2,442 | (77,333) |
| Net cash used in operating activities | (572,109) | (850,089) |
| Cash Flows from Investing Activities | ||
| Net cash used in investing activities | --- | --- |
| Cash Flows from Financing Activities | ||
| Proceeds from sale of common stock | --- | 10,000 |
| Proceeds from related party notes payable and advances | 515,000 | 710,000 |
| Proceeds from third party notes payable and advances | 500,000 | 305,000 |
| Repayment of related party notes payable and advances | (39,840) | --- |
| Repayment of third party notes payable | (427,343) | (230,951) |
| Net cash provided by financing activities | 547,817 | 794,049 |
| Net decrease in cash | (24,292) | (56,040) |
| Cash, beginning of period | 37,136 | 76,241 |
| Cash, end of period | 12,844 | 20,201 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗